These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25770292)

  • 1. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
    Pabla N; Sparreboom A
    Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
    Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical investigations with epothilones in breast cancer models.
    Burris HA
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
    De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.